胶质母细胞瘤的代谢与翻译后脆弱性:二硫死亡、糖基化及对 CAR-T 治疗的启示
Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.
胶质母细胞瘤(GB)仍是治疗抵抗性最强的实体瘤之一,其特征是显著的代谢可塑性、瘤内异质性和高度免疫抑制的微环境。
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.
胶质母细胞瘤(GB)仍是治疗抵抗性最强的实体瘤之一,其特征是显著的代谢可塑性、瘤内异质性和高度免疫抑制的微环境。
Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clini
初步临床经验表明,针对儿童和年轻成人 CNS 肿瘤的 CAR-T 细胞疗法具有生物学活性且临床可行,其毒性特征独特但可控。
Advances in CAR-T therapy for central nervous system tumors.
CAR-T 细胞疗法在中枢神经系统肿瘤中的应用已取得显著进展;
Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.
自然杀伤(NK)细胞是固有免疫的关键组成部分,无需预先致敏即具有清除肿瘤细胞的能力。
Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st
检索获得324条记录;去除103条重复记录;筛选221篇标题和摘要;审阅180篇全文;由两名独立评价者提取34项研究。
CAR T-cell therapy in pediatric brain tumors: a narrative review with comparative analysis of clinical trial eligibility criteria.
符合纳入标准的研究共18项,包括临床前模型、早期临床试验和转化研究。
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法,CAR-T细胞疗法仍处于快速发展阶段。CAR-T细胞相关领域在未来仍将是研究热点。
Clinical progress in the development of CAR T cells to treat malignant glioma.
在研 CAR-T 细胞疗法的快速演进预示着胶质瘤治疗未来的巨大潜力。
Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings.
基于嵌合抗原受体(CAR)T 细胞的免疫治疗已显示出治疗血液肿瘤的潜力,其在实体瘤中的应用目前正被广泛研究。
MEMBER ACCOUNT
登录成功会直接打开下一页。